Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Spravato - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Spravato

Approved

STANDARD

Spravato

Renaissance Lakewood LLC🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: dd8b12ead355616e
Company: Renaissance Lakewood LLC
Type: Standard

Approval Details

Approval Id: dd8b12ead355616e
Drug Approval Philippines Name: Spravato
Product Name: Spravato
Registration Number: DR-XY47611
Brand Name: Spravato
Generic Name: Esketamine (as hydrochloride)
Dosage Form: Nasal Solution (Spray)
Dosage Strength: 28 mg
Manufacturer: Renaissance Lakewood LLC
Importer: Johnson & Johnson (Philippines), Inc.
Company Detail Path: /organization/renaissance-lakewood-llc
Issuance Date: 16 December 2021
Expiry Date: 16 December 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

dd8b12ead355616e

Type

Standard

Back to Philippines FDA Approvals